Publication: Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
No Thumbnail Available
Identifiers
Publication date
2012-02-21
Authors
Magro, Margarita
Mas-Lloret, Vicente ISCIII 
Chappell, Keith
Vazquez-Alcaraz, Monica ISCIII
Cano, Olga ISCIII
Luque, Daniel ISCIII
Melero, Jose Antonio ISCIII
Palomo-Sanz, Concepcion ISCIII
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
National Academy of Sciences
Metrics
Export
Abstract
Human respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at very high risk of severe hRSV infections. Palivizumab, as most anti-F antibodies so far described, recognizes an epitope that is shared by the two conformations in which hRSV_F can fold, the metastable prefusion form and the highly stable postfusion conformation. We now describe a unique class of antibodies specific for the prefusion form of this protein that account for most of the neutralizing activity of either a rabbit serum raised against a vaccinia virus recombinant expressing hRSV_F or a human Ig preparation (Respigam), which was used for prophylaxis before Palivizumab. These antibodies therefore offer unique possibilities for immune intervention against hRSV, and their production should be assessed in trials of hRSV vaccines.
Description
Keywords
DeCS Terms
Bibliographic citation
Proc Natl Acad Sci USA. 2012 Feb 21;109(8):3089-94.